MiRNAs: Main Players of Cancer Drug Resistance Target ABC Transporters

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Date 2025 Jan 14

PMID 39808313

Authors

Forogh Mohammadi

Masoumeh Nejatollahi

Farhad Sheikhnia

Yaser Ebrahimi

Mahya Mohammadi

Vahid Rashidi

Shahin Alizadeh-Fanalou

Bita Azizzadeh

Maryam Majidinia

Affiliations

Soon will be listed here.

Abstract

Chemotherapy remains the cornerstone of cancer treatment; however, its efficacy is frequently compromised by the development of chemoresistance. Multidrug resistance (MDR), characterized by the refractoriness of cancer cells to a wide array of chemotherapeutic agents, presents a significant barrier to achieving successful and sustained cancer remission. One critical factor contributing to this chemoresistance is the overexpression of ATP-binding cassette (ABC) transporters. Furthermore, additional mechanisms, such as the malfunctioning of apoptosis, alterations in DNA repair systems, and resistance mechanisms inherent to cancer stem cells, exacerbate the issue. Intriguingly, microRNAs (miRNAs) have demonstrated potential in modulating chemoresistance by specifically targeting ABC transporters, thereby offering promising new avenues for overcoming drug resistance. This narrative review aims to elucidate the molecular underpinnings of drug resistance, with a particular focus on the roles of ABC transporters and the regulatory influence of miRNAs on these transporters.

References

Adamska A, Ferro R, Lattanzio R, Capone E, Domenichini A, Damiani V . ABCC3 is a novel target for the treatment of pancreatic cancer. Adv Biol Regul. 2019; 73:100634. DOI: 10.1016/j.jbior.2019.04.004. View

Adeshakin F, Adeshakin A, Afolabi L, Yan D, Zhang G, Wan X . Mechanisms for Modulating Anoikis Resistance in Cancer and the Relevance of Metabolic Reprogramming. Front Oncol. 2021; 11:626577. PMC: 8039382. DOI: 10.3389/fonc.2021.626577. View

Afonso-Grunz F, Muller S . Principles of miRNA-mRNA interactions: beyond sequence complementarity. Cell Mol Life Sci. 2015; 72(16):3127-41. PMC: 11114000. DOI: 10.1007/s00018-015-1922-2. View

Nour M, Hajiasgharzadeh K, Kheradmand F, Asadzadeh Z, Bolandi N, Baradaran B . Nicotinic acetylcholine receptors in chemotherapeutic drugs resistance: An emerging targeting candidate. Life Sci. 2021; 278:119557. DOI: 10.1016/j.lfs.2021.119557. View

Algorashi I, Goldvaser H, Ribnikar D, Cescon D, Amir E . Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. Cancer Treat Rev. 2018; 70:138-143. DOI: 10.1016/j.ctrv.2018.08.009. View

Alizadeh-Fanalou S, Hosseinkhani S, Nazarizadeh A, Ezzati-Mobaser S, Hesari Z, Aziminezhadan P . MiR-613 Promotes Cell Death in Breast Cancer Cells by Downregulation of Nicotinamide Phosphoribosyltransferase and Reduction of NAD. DNA Cell Biol. 2021; 40(7):1026-1036. DOI: 10.1089/dna.2021.0330. View

Alla V, Kowtharapu B, Engelmann D, Emmrich S, Schmitz U, Steder M . E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle. 2012; 11(16):3067-78. PMC: 3442917. DOI: 10.4161/cc.21476. View

Al-Momany B, Hammad H, Ahram M . Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p. Curr Mol Pharmacol. 2021; 14(5):860-870. DOI: 10.2174/1874467214666210531170355. View

Alvarez M, Paull K, Monks A, Hose C, Lee J, Weinstein J . Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. J Clin Invest. 1995; 95(5):2205-14. PMC: 295832. DOI: 10.1172/JCI117910. View

10.

Amawi H, Sim H, Tiwari A, Ambudkar S, Shukla S . ABC Transporter-Mediated Multidrug-Resistant Cancer. Adv Exp Med Biol. 2019; 1141:549-580. DOI: 10.1007/978-981-13-7647-4_12. View

11.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin M, Singh P . Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat. 2017; 163(3):461-474. PMC: 5427146. DOI: 10.1007/s10549-017-4202-z. View

12.

Asaduzzaman M, Constantinou S, Min H, Gallon J, Lin M, Singh P . Correction to: Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer. Breast Cancer Res Treat. 2018; 167(2):605-606. PMC: 6828501. DOI: 10.1007/s10549-017-4633-6. View

13.

Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S . Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol. 2012; 180(6):2490-503. PMC: 3378910. DOI: 10.1016/j.ajpath.2012.02.024. View

14.

Bao J, Xu Y, Wang Q, Zhang J, Li Z, Li D . miR-101 alleviates chemoresistance of gastric cancer cells by targeting ANXA2. Biomed Pharmacother. 2017; 92:1030-1037. DOI: 10.1016/j.biopha.2017.06.011. View

15.

Begicevic R, Falasca M . ABC Transporters in Cancer Stem Cells: Beyond Chemoresistance. Int J Mol Sci. 2017; 18(11). PMC: 5713331. DOI: 10.3390/ijms18112362. View

16.

Beis K . Structural basis for the mechanism of ABC transporters. Biochem Soc Trans. 2015; 43(5):889-93. DOI: 10.1042/BST20150047. View

17.

Bhattacharjee M, Ghosh A, Das S, Sarker S, Bhattacharya S, Das A . Systemic Codelivery of Thymoquinone and Doxorubicin by Targeted Mesoporous Silica Nanoparticle Sensitizes Doxorubicin-Resistant Breast Cancer by Interfering between the MDR1/P-gp and miR 298 Crosstalk. ACS Biomater Sci Eng. 2024; 10(10):6314-6331. DOI: 10.1021/acsbiomaterials.4c01081. View

18.

Bi D, Yin C, Zhang X, Yang N, Xu J . MiR-183 functions as an oncogene by targeting ABCA1 in colon cancer. Oncol Rep. 2016; 35(5):2873-9. DOI: 10.3892/or.2016.4631. View

19.

Blair B, Larson C, Adams P, Abada P, Safaei R, Howell S . Regulation of copper transporter 2 expression by copper and cisplatin in human ovarian carcinoma cells. Mol Pharmacol. 2010; 77(6):912-21. PMC: 2879916. DOI: 10.1124/mol.109.062836. View

20.

Borst P, Evers R, Kool M, Wijnholds J . A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst. 2000; 92(16):1295-302. DOI: 10.1093/jnci/92.16.1295. View